Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Immunotherapy for GPC3+ HCC
NCT02723942Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Jun 2015
- Primary completion
- Aug 2016
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of BOXR1030 in hepatocellular carcinoma (HCC), sponsored by Fuda Cancer Hospital. Planned start Jun 2015; status: withdrawn.
02
Drugs
BOXR1030
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02723942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723942.